Want to join the conversation?
$ESRX's PBM gross profit for 3Q15 rose by 4.7% from last year. This increase is due to better management of ingredient costs and formulary, as well as cost savings from rise in aggregate generic fill rate. Additionally, this increase is due to $45.2MM of transaction and integration costs for 3Q15, down from $65MM in 3Q14.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.